Ajo LP acquired a new position in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) during the second quarter, Holdings Channel reports. The firm acquired 14,521 shares of the company’s stock, valued at approximately $779,000. Ajo LP owned 0.10% of Anika Therapeutics at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of ANIK. Renaissance Technologies LLC raised its position in Anika Therapeutics by 165.8% in the first quarter. Renaissance Technologies LLC now owns 300,400 shares of the company’s stock valued at $13,434,000 after buying an additional 187,400 shares during the last quarter. Emerald Acquisition Ltd. bought a new stake in Anika Therapeutics during the second quarter valued at $6,541,000. Bogle Investment Management L P DE raised its stake in Anika Therapeutics by 118.1% in the first quarter. Bogle Investment Management L P DE now owns 110,969 shares of the company’s stock valued at $4,962,000 after buying an additional 60,087 shares in the last quarter. Turner Investments L.P. bought a new stake in Anika Therapeutics during the second quarter valued at $2,414,000. Finally, Fisher Asset Management LLC raised its stake in Anika Therapeutics by 308.7% in the first quarter. Fisher Asset Management LLC now owns 57,719 shares of the company’s stock valued at $2,792,000 after buying an additional 43,595 shares in the last quarter. Institutional investors and hedge funds own 77.85% of the company’s stock.

Anika Therapeutics Inc. (NASDAQ:ANIK) traded down 0.46% during mid-day trading on Thursday, hitting $47.71. 31,426 shares of the stock traded hands. The company has a 50-day moving average of $48.18 and a 200 day moving average of $47.84. The firm has a market capitalization of $705.01 million, a P/E ratio of 20.82 and a beta of 1.50. Anika Therapeutics Inc. has a 1-year low of $30.93 and a 1-year high of $54.96.

Anika Therapeutics (NASDAQ:ANIK) last issued its earnings results on Wednesday, July 27th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.13. The business earned $26.60 million during the quarter, compared to analyst estimates of $24.75 million. Anika Therapeutics had a return on equity of 17.24% and a net margin of 33.77%. Anika Therapeutics’s revenue for the quarter was up 16.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.51 earnings per share. On average, equities research analysts anticipate that Anika Therapeutics Inc. will post $2.00 EPS for the current year.

Separately, Zacks Investment Research upgraded shares of Anika Therapeutics from a “hold” rating to a “strong-buy” rating and set a $58.00 price objective for the company in a research note on Monday, August 1st.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.

5 Day Chart for NASDAQ:ANIK

Want to see what other hedge funds are holding ANIK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anika Therapeutics Inc. (NASDAQ:ANIK).

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.